Roche

News

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

News

J&J's oral IL-23 drug backed for psoriasis in EU

J&J's oral psoriasis drug Icotyde heads up the list of new therapies recommended for EU approval at the CHMP's July meeting.

News

England to start screening newborns for rare disease SMA

All newborns in England will be screened for rare muscle-wasting disease spinal muscular atrophy from 2027, in a landmark move for patients.

News

Roche abandons two Huntington's drug candidates

Roche has scrapped two drugs for Huntington's disease – tominersen and RG6496 – after seeing disappointing results in clinical trials.

News

Roche looks to Astex in $515m breast cancer deal

Roche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

J&J's oral IL-23 drug backed for psoriasis in EU

England to start screening newborns for rare disease SMA

Roche abandons two Huntington's drug candidates

Roche looks to Astex in $515m breast cancer deal

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks